Get the Stockscreener App
20.05
3.79%
-0.79
After Hours:
20.10
0.05
+0.25%
Evommune Inc stock is traded at $20.05, with a volume of 344.58K.
It is down -3.79% in the last 24 hours and down -12.52% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$20.84
Open:
$20.9
24h Volume:
344.58K
Relative Volume:
0.94
Market Cap:
$722.17M
Revenue:
$10.00M
Net Income/Loss:
$-75.99M
P/E Ratio:
-8.3986
EPS:
-2.3873
Net Cash Flow:
$-80.36M
1W Performance:
-2.15%
1M Performance:
-12.52%
6M Performance:
+26.42%
1Y Performance:
+0.00%
1-Day Range:
$19.98
$20.92
1-Week Range:
$19.77
$21.61
52-Week Range:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
20.05 | 750.62M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Resumed | Oppenheimer | Outperform |
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
Evommune Inc. (EVMN) Declines 4.16% as Stock Tests Key Support at $18.84Double EMA - newsline.com
Evommune Inc. (EVMN) Slips 4.16% as Biotech Sentiment SoftensMomentum Stock Picks - newsline.com
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
Evommune director Cohen sells $123,093 in stock By Investing.com - Investing.com India
Insider Sell: Luis Pena Sells Shares of Evommune Inc (EVMN) - GuruFocus
Evommune CSO Patel sells $379k, acquires $51k in stock - Investing.com UK
Evommune president & CEO Luis C. Pena sells $381,736 in stock - Investing.com Nigeria
Evommune president & CEO Luis C. Pena sells $381,736 in stock By Investing.com - Investing.com South Africa
Evommune director Cohen sells $123,093 in stock - Investing.com
Evommune CSO Patel sells $379k, acquires $51k in stock By Investing.com - Investing.com Australia
Evommune (EVMN) grants director 15,673 stock options at $19.82 - Stock Titan
Evommune (EVMN) CEO Luis C. Pena sells 16,787 shares under 10b5-1 plan - Stock Titan
Evommune (EVMN) director sells 6,056 shares and receives option grant - Stock Titan
Broker files proposed sale of EVMN (NYSE: EVMN) — 9,258 shares listed - Stock Titan
Evommune (EVMN) elects directors and ratifies BDO as auditor - Stock Titan
Evommune (EVMN) investors back board nominees and ratify BDO USA as 2026 auditor - Stock Titan
EVMN: Directors and auditor were approved, with no shareholder questions and quorum established - TradingView
Evommune CFO Kyle Carver sells $415,117 of EVMN stock By Investing.com - Investing.com UK
Evommune chief business & legal officer sells $324,711 in stock By Investing.com - Investing.com Australia
Evommune CFO Kyle Carver sells $415,117 of EVMN stock - Investing.com
Evommune chief business & legal officer sells $324,711 in stock - Investing.com
Evommune (EVMN) officer exercises options and sells 14,223 shares under 10b5-1 plan - Stock Titan
Evommune (EVMN) CFO sells 18,175 shares under 10b5-1 plan - Stock Titan
Morgan Stanley Smith Barney (EVMN) files Form 144 listing 24,225 shares - Stock Titan
15,000-Share Rule 144 Notice for EVMN (EVMN) by Morgan Stanley - Stock Titan
Number of shareholders of Evommune, Inc. – NYSE:EVMN - TradingView
[144] Evommune, Inc. SEC Filing - Stock Titan
EVMN (NYSE: EVMN) broker files to sell 22,500 shares on 05/28/2026 - Stock Titan
Evommune Inc. (EVMN) Slides 1.46% Amid Cautious Sector Tone; Support at $21.85 in FocusDonchian Channel - newsline.com
H.C. Wainwright Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune Inc. (EVMN) Q1 2026 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressProduct Revenue Analysis - The Legal Advocate
H.C. Wainwright reiterates Evommune stock rating on trial progress By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Evommune stock rating on trial progress - Investing.com
Number of shareholders of Evommune, Inc. – BX:EVMN - TradingView
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Evommune (EVMN) Institutional Ownership 2026 - MarketBeat
Oppenheimer Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune Inc Stock (EVMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):